体外诊断医疗器械法规对实验室自建检测的影响与建议
荷兰实验室专业学会成立IVDR工作组,起草了解读IVDR相关条款的指南文件,并收集利益相关方反馈完善该文件。本文向欧洲同行介绍IVDR对实验室自建检测的影响及满足其要求的可能方法。
要点
- IVDR于2022年5月生效,对临床实验室使用实验室自建检测(LDT)施加限制。
- 荷兰多学科工作组起草了IVDR相关条款的解释性指南文件。
- 本文提出满足IVDR对LDT要求的潜在有用方法。
核心结论
- IVDR对临床实验室使用实验室自建检测(LDT)施加限制,荷兰工作组提供了统一解读和满足要求的潜在方法。
研究设计与样本
- 荷兰实验室专业学会成立IVDR工作组,起草解释性指南文件并收集反馈完善。
主要发现
- IVDR对体外诊断医疗器械制造商和临床实验室均有重大影响,尤其限制LDT的使用。
临床怎么用
- 临床实验室可参考该指南文件准备应对IVDR对LDT的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The in vitro diagnostic medical devices regulation (IVDR) will take effect in May 2022. This regulation has a large impact on both the manufacturers of in vitro diagnostic medical devices (IVD) and clinical laboratories. For clinical laboratories, the IVDR poses restrictions on the use of laboratory developed tests (LDTs). To provide a uniform interpretation of the IVDR for colleagues in clinical practice, the IVDR Task Force was created by the scientific societies of laboratory specialties in the Netherlands. A guidance document with explanations and interpretations of relevant passages of the IVDR was drafted to help laboratories prepare for the impact of this new legislation. Feedback from interested parties and stakeholders was collected and used to further improve the document. Here we would like to present our approach to our European colleagues and inform them about the impact of the IVDR and, importantly we would like to present potentially useful approaches to fulfill the requirements of the IVDR for LDTs.
引用
- Bank PCD, Jacobs LHJ, van den Berg SAA, et al. The end of the laboratory developed test as we know it? Recommendations from a national multidisciplinary taskforce of laboratory specialists on the interpretation of the IVDR and its complications. Clin Chem Lab Med. 2020. PMID: 33554568. doi:10.1515/cclm-2020-1384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。